Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Gains from Sales and Divestitures: 2020-2025

Historic Gains from Sales and Divestitures for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $278,130.

  • Kymera Therapeutics' Gains from Sales and Divestitures rose 64.84% to $278,130 in Q3 2025 from the same period last year, while for Sep 2025 it was $278,130, marking a year-over-year increase of 64.84%. This contributed to the annual value of $174,463 for FY2024, which is 341.56% up from last year.
  • Per Kymera Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $278,130 for Q3 2025, which was up 23.68% from $224,882 recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Gains from Sales and Divestitures ranged from a high of $278,130 in Q3 2025 and a low of $14,215 during Q1 2022.
  • In the last 3 years, Kymera Therapeutics' Gains from Sales and Divestitures had a median value of $146,869 in 2025 and averaged $125,361.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 56.56% in 2022, then skyrocketed by 371.47% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $84,859 in 2021, then plummeted by 56.56% to $36,866 in 2022, then grew by 7.17% to $39,511 in 2023, then spiked by 341.56% to $174,463 in 2024, then soared by 64.84% to $278,130 in 2025.
  • Its Gains from Sales and Divestitures was $278,130 in Q3 2025, compared to $224,882 in Q2 2025 and $146,869 in Q1 2025.